Table 1.
ZIKV IgG ELISA and VNT results in 2017 cohort and pre-ZIKV cohort
| Participants (% of total) | Positive ZIKV IgG ELISA result, No. (% [95% CI]) | Positive VNT result, No. (% [95% CI]) | |
|---|---|---|---|
| 2017 Cohort | |||
| Total cohort | 770 (100) | 530 (68.8 [65.5–72.0]) | 270 (35.1 [31.8–38.5]) |
| Paramaribo | 424 (55.1) | 290 (68.4 [63.8–72.6]) | 162 (38.2 [33.7–42.9]) |
| Laduani | 191 (24.8) | 159 (83.2 [77.3–87.9]) | 70 (36.7 [30.1–43.7]) |
| Kwamalasamutu | 155 (20.1) | 77 (49.7 [41.9–57.5]) | 38 (24.5 [18.4–31.9]) |
| Sex | |||
| Male | 314 (40.8) | 219 (69.7 [64.5–74.6]) | 106 (33.8 [28.8–39.2]) |
| Female | 455 (59.1) | 311 (68.4 [63.9–72.5]) | 164 (36.0 [31.8–40.6]) |
| Unknown | 1 (0.1) | 0 | 0 |
| Age | |||
| 18–31 | 203 (26.4) | 132 (65.0 [58.2–71.3]) | 74 (36.5 [30.1–43.3]) |
| 32–45 | 188 (24.4) | 123 (65.4 [58.4–71.6]) | 55 (29.3 [23.2–36.1]) |
| 46–59 | 210 (27.3) | 149 (71.0 [64.5–76.7]) | 71 (33.8 [27.8–40.5]) |
| ≥60 | 169 (21.9) | 126 (74.6 [67.5–80.5]) | 70 (41.4 [34.3–49.0]) |
| YFV vaccination status (Paramaribo only) | |||
| Vaccinated | 166 (39.2) | 114 (68.7 [61.3–75.2]) | 69 (41.6 [34.3–49.2]) |
| Not vaccinated | 114 (26.9) | 84 (73.7 [64.9–80.9]) | 41 (36.0 [27.7–45.1]) |
| Unknown | 144 (33.9) | 96 (66.7 [58.6–73.8]) | 52 (36.1 [28.7–44.2]) |
| Experienced ZIKV-related symptoms the past 2 years (Paramaribo only) | |||
| One or more symptoms reported | 159 (37.5) | 111 (69.8 [62.3–76.4]) | 55 (34.6 [27.6–42.3]) |
| No symptoms reported | 265 (62.5) | 183 (69.1 [63.3–74.3]) | 107 (40.4 [34.6–46.4]) |
| Pre-ZIKV cohort | |||
| Total cohort | 44 (100) | 23 (52.3 [37.9–66.2]) | 0 |